Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.60 |
| ▸ | TK2 | O00142 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | TK1 | P04183 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23394587 | 0.88 | RNASE1 (0.59) | RNASE1TK2SLC6A2TK1LMNA | |
| SCHEMBL5838118 | 0.86 | RNASE1 (0.55) | RNASE1TK2SLC6A2TK1LMNA | |
| SCHEMBL23914022 | 0.86 | RNASE1 (0.57) | RNASE1TK2SLC6A2TK1LMNA | |
| SCHEMBL19407973 | 0.85 | RNASE1 (0.71) | RNASE1TK2SLC6A2TK1LMNA | |
| SCHEMBL3337696 | 0.85 | RNASE1 (0.71) | RNASE1TK2SLC6A2TK1LMNA | |
| SCHEMBL774263 | 0.83 | RNASE1 (0.68) | RNASE1TK2SLC6A2TK1LMNA | |
| SCHEMBL14681227 | 0.83 | RNASE1 (0.68) | RNASE1TK2SLC6A2TK1LMNA | |
| SCHEMBL16287348 | 0.83 | RNASE1 (0.68) | RNASE1TK2SLC6A2TK1LMNA | |
| SCHEMBL767324 | 0.83 | RNASE1 (0.68) | RNASE1TK2SLC6A2TK1LMNA | |
| SCHEMBL16349867 | 0.83 | RNASE1 (0.71) | RNASE1TK2SLC6A2TK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7038103-B2 | Solution phase biopolymer synthesis | HUBERT KOSTER (CH) | 2006-05-02 | — | — | US | claimed |
| US-20020016451-A1 | SOLUTION PHASE BIOPOLYMER SYNTHESIS | CAPROTEC BIOANALYTICS GMBH (DE) | 2002-02-07 | — | — | US | claimed |
| US-20020007048-A1 | Solution Phase Biopolymer Synthesis | CAPROTEC BIOANALYTICS GMBH (DE) | 2002-01-17 | — | — | US | claimed |
| US-7094943-B2 | Solution phase biopolymer synthesis | Köster, Hubert (US) | 2006-08-22 | — | — | US | disclosed |
| US-7038103-B2 | Solution phase biopolymer synthesis | HUBERT KOSTER (CH) | 2006-05-02 | — | — | US | disclosed |
| US-20020016451-A1 | SOLUTION PHASE BIOPOLYMER SYNTHESIS | CAPROTEC BIOANALYTICS GMBH (DE) | 2002-02-07 | — | — | US | disclosed |
| US-20020007048-A1 | Solution Phase Biopolymer Synthesis | CAPROTEC BIOANALYTICS GMBH (DE) | 2002-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007048-A1 | Solution Phase Biopolymer Synthesis | RNGTT, SGMS1, SPNS2 | RNASE1 195/4885TK2 1942/4885SLC6A2 1887/4885 |
| US-20020016451-A1 | SOLUTION PHASE BIOPOLYMER SYNTHESIS | RNGTT, SGMS1, SPNS2 | RNASE1 195/4885TK2 1942/4885SLC6A2 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.